Acute gout attacks · people with chronic gout
Allopurinol showed no clear difference in acute gout attacks compared with benzbromarone (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol showed no clear difference in proportion achieving target serum urate compared with benzbromarone (moderate certainty).
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol probably leads to higher proportion achieving target serum urate compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).
1 finding from 1 review
Serious adverse effects · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Pain reduction · people with chronic gout
1 finding from 1 review
Function · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in acute gout attacks compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Intervention not reported
Pain Self report · people with osteoarthritis of the hip
1 finding from 1 review
Intervention not reported
Physical function · people with osteoarthritis of the hip
1 finding from 1 review
Intervention not reported
Quality of life · people with osteoarthritis of the hip
1 finding from 1 review
Intervention not reported
Withdrawals or dropouts · people with osteoarthritis of the hip
The intervention showed no clear difference in withdrawals or dropouts (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not reported · people with osteoarthritis of the hip
The review found no eligible studies for this question.
1 finding from 1 review